A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
Clinical trial NCT04722887 · COMPLETED
Trial details
- NCT number
- NCT04722887
- Sponsor
- Grifols Therapeutics LLC
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-13
- Primary completion
- 2025-08-01
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.